Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.38 |
| ▸ | FEN1 | P39748 | 4/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391421 | 1.00 | HTR1B (1.00) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| SCHEMBL29385708 | 1.00 | HTR1B (1.00) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| Hydrochloric Acid SCHEMBL5746097 | 0.99 | HTR1B (0.97) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| SCHEMBL8469545 | 0.99 | HTR1B (0.97) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| SCHEMBL5749142 | 0.91 | HTR1B (0.84) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| Fumaric Acid SCHEMBL5773986 | 0.89 | HTR1B (0.80) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| Maleic Acid SCHEMBL5773984 | 0.89 | HTR1B (0.80) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| SCHEMBL5749044 | 0.88 | HTR1B (0.78) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| SCHEMBL5749623 | 0.88 | HTR1B (0.78) | HTR1BHTR2BGPR65AURKAPDPK1 | |
| Hydrochloric Acid SCHEMBL5748497 | 0.85 | HTR1B (0.74) | HTR1BHTR2BGPR65AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901474-B1 | ARYL PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | claimed |
| JP-2004500333-A | — | — | 2004-01-08 | — | — | JP | claimed |
| EP-1200093-B1 | USE OF 2-AMINO-4-(4-FLUORONAPHTH-1-YL)-6-ISOPROPYLPYRIMIDINE IN THE TREATMENT OF GI DISORDERS | PHARMAGENE LAB LTD (GB) | 2003-09-24 | — | — | EP | claimed |
| EP-1321169-A1 | Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament | Biofrontera Pharmaceuticals AG (DE) | 2003-06-25 | — | — | EP | claimed |
| CN-1109675-C | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2003-05-28 | — | — | CN | claimed |
| EP-1200093-A2 | USE OF 2-AMINO-4-(4-FLUORONAPHTH-1-YL)-6-ISOPROPYLPYRIMIDINE IN THE TREATMENT OF GI DISORDERS | Pharmagene Laboratories Ltd (GB) | 2002-05-02 | — | — | EP | claimed |
| WO-2001008668-A2 | USE OF 2-AMINO-4-(4-FLUORONAPHTH-1-YL)-6-ISOPROPYLPYRIMIDINE IN THE TREATMENT OF GI DISORDERS | PHARMAGENE LABORATORIES LTD (GB) | 2001-02-08 | — | — | WO | claimed |
| US-5952331-A | SELECTIVE 5HT2B ANTAGONISTS; SEROTONIN RECEPTOR ANTAGONIST; TREATING DISORDERS OF THE GASTROINTESTINAL TRACK, RESTENOSIS, ASTHMA AND OBSTRUCTIVE AIRWAY DISEASE, PROSTATIC HYPERPLASIA, GENERALIZED ANXIETY, PANIC DISORDER | SYNTEX (USA) INC. (US) | 1999-09-14 | — | — | US | claimed |
| CN-1223641-A | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1999-07-21 | — | — | CN | claimed |
| EP-0901474-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | claimed |
| US-5863924-A | Aryl pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1999-01-26 | — | — | US | claimed |
| WO-1997044326-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-27 | — | — | WO | claimed |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4340940-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | The Regents of University of California (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220370381-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| CN-1223641-A | Aryl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1999-07-21 | — | — | CN | disclosed |
| EP-0901474-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5863924-A | Aryl pyrimidine derivatives | SYNTEX (U.S.A.) INC. (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997044326-A1 | ARYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | HTR1B 4/4885HTR2B 1/4885GPR65 323/4885 |
| US-20220370381-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | PSEN2, EPM2A, TPH2 | HTR1B 33/4885HTR2B 53/4885GPR65 1483/4885 |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | ADORA2B, ADORA2A, ANXA3 | HTR1B 873/4885HTR2B 276/4885GPR65 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.